KIT and acute myeloid leukemia: BC281 treatment resulted in a significant reduction of percentage of AML blasts (c-Kit+CD11b+) in the BM (Supplementary Fig. 27F) as well as frequency of myeloid-derived suppressor cells (CD11b+Gr-1+) (Supplementary Fig. 27G).